Analyzing Genmab A/S (NASDAQ:GMAB) & Lexaria Bioscience (NASDAQ:LEXX)
Analyzing Genmab A/S (NASDAQ:GMAB) & Lexaria Bioscience (NASDAQ:LEXX)
Genmab A/S (NASDAQ:GMAB – Get Rating) and Lexaria Bioscience (NASDAQ:LEXX – Get Rating) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.
Genmab A/S(納斯達克：GMAB-GET評級)和利康生物(納斯達克：Lexx-GET評級)都是醫藥公司，但哪一家是優勢投資？我們將根據這兩家公司的機構所有權、分析師建議、盈利能力、估值、風險、收益和股息的實力進行比較。
Risk and Volatility
風險和波動性
Genmab A/S has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.04, meaning that its share price is 96% less volatile than the S&P 500.
Genmab A/S的貝塔係數為0.85，這意味着其股價的波動性比標準普爾500指數低15%。相比之下，Lexaria Bioscience的貝塔係數為0.04，這意味着其股價的波動性比標準普爾500指數低96%。
Institutional & Insider Ownership
機構與內部人持股
5.5% of Genmab A/S shares are owned by institutional investors. Comparatively, 9.4% of Lexaria Bioscience shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 9.6% of Lexaria Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Genmab A/S公司5.5%的股份由機構投資者持有。相比之下，Lexaria Bioscience 9.4%的股份由機構投資者持有。Genmab A/S公司1.5%的股份由內部人士持有。相比之下，Lexaria Bioscience 9.6%的股份由內部人士持有。強大的機構持股表明，對衝基金、捐贈基金和大型基金管理公司相信，一隻股票有望實現長期增長。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| Genmab A/S | 38.42% | 17.12% | 15.37% |
| Lexaria Bioscience | -3,960.36% | -63.62% | -62.36% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| Genmab A/S | 38.42% | 17.12% | 15.37% |
| Lexaria生物科學 | -3,960.36% | -63.62% | -62.36% |
Analyst Ratings
分析師評級
This is a breakdown of recent ratings and price targets for Genmab A/S and Lexaria Bioscience, as reported by MarketBeat.com.
這是MarketBeat.com報道的Genmab A/S和Lexaria Bioscience最近的評級和目標價細目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Genmab A/S | 1 | 7 | 2 | 0 | 2.10 |
| Lexaria Bioscience | 0 | 0 | 0 | 0 | N/A |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| Genmab A/S | 1 | 7 | 2 | 0 | 2.10 |
| Lexaria生物科學 | 0 | 0 | 0 | 0 | 不適用 |
Genmab A/S presently has a consensus target price of $37.15, indicating a potential upside of 13.81%. Given Genmab A/S's higher possible upside, equities analysts clearly believe Genmab A/S is more favorable than Lexaria Bioscience.
Genmab A/S目前的共識目標價為37.15美元，表明潛在上行13.81%。鑑於Genmab A/S更有可能上行，股票分析師顯然認為Genmab A/S比Lexaria Bioscience更有利。
Earnings & Valuation
收益與估值
This table compares Genmab A/S and Lexaria Bioscience's revenue, earnings per share and valuation.
該表格比較了Genmab A/S和Lexaria Bioscience的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Genmab A/S | $1.35 billion | 15.92 | $478.57 million | $0.90 | 36.27 |
| Lexaria Bioscience | $720,000.00 | 20.58 | -$4.03 million | N/A | N/A |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| Genmab A/S | 13.5億美元 | 15.92 | 4.7857億美元 | $0.90 | 36.27 |
| Lexaria生物科學 | $720,000.00 | 20.58 | -403萬元 | 不適用 | 不適用 |
Genmab A/S has higher revenue and earnings than Lexaria Bioscience.
Genmab A/S的收入和收益高於Lexaria Bioscience。
Summary
摘要
Genmab A/S beats Lexaria Bioscience on 8 of the 11 factors compared between the two stocks.
Genmab A/S在比較兩隻股票的11個因素中有8個超過了Lexaria Bioscience。
About Genmab A/S
關於Genmab A/S
(Get Rating)
(獲取評級)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company's also develops products, which is in Phase 2 comprise Teclistamab for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Genmab A/S主要在丹麥開發用於治療癌症和其他疾病的抗體療法。該公司銷售用於治療多發性骨髓瘤(MM)患者的人類單抗DARZALEX；用於治療甲狀腺眼病的teprotomumab；用於治療慢性淋巴細胞白血病(CLL)和多發性硬化症的人類單抗Ofatumurnab；以及用於晚期或轉移性胃癌、食道癌和非小細胞肺癌的Amivantamab。其產品包括用於治療MM、非MM血癌和AL澱粉樣變性的daratumab；GEN1047；用於治療宮頸癌、卵巢癌和實體瘤的tisotomab vedotin；用於治療實體瘤的DuoBody-PD-L1x4-1BB和DuoBody-CD40x4-1BB；用於復發/難治性瀰漫性大B細胞淋巴瘤和慢性淋巴細胞白血病的Epcoritamab；以及用於治療血液系統惡性腫瘤的HexaBody-CD38和DuoHexaBody-CD37。該公司還開發處於第二階段的產品，包括用於血管閉塞危機的Tecistamab；用於治療霍奇金淋巴瘤和實體瘤的CamidanLumab Tesiine；用於治療MM的JNJ-64007957和JNJ-64407564；用於治療乳糜瀉的PRV-015；用於治療血友病A的MIM8；以及用於治療多系統萎縮疾病的Lu AF82422。此外，它還有大約20個活躍的臨牀前項目。該公司與Seagen Inc.有商業許可和合作協議，共同開發tisotomab vedotin。它還與CureVac AG簽訂了研究和開發不同的基於信使核糖核酸的抗體產品的合作協議；AbbVie公司開發epcoritamab；與BioNTech公司、Janssen公司、Novo Nordisk A/S公司、Blink Biomedical SAS公司和Bolt BioTreateutics公司合作。Genmab A/S公司成立於1999年，總部設在丹麥哥本哈根。
About Lexaria Bioscience
關於Lexaria Bioscience
(Get Rating)
(獲取評級)
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 – 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Lexaria Bioscience Corp.是一家生物技術公司。其專利藥物傳遞技術DehyTECH通過促進有效的口服傳遞，改善了活性藥物成分進入血液的方式。該公司的DehyTECH已經證明，與標準行業配方相比，大麻類藥物和尼古丁的生物吸收增加了5-10倍，在某些情況下，大麻類藥物的生物吸收增加了27倍，起效時間從1-2小時減少到幾分鐘，並掩蓋了不想要的味道；還在評估口服抗病毒藥物、非類固醇抗炎藥(NSAID)、PDE5抑制劑和其他藥物。脱氫TECH還可以有效地通過血腦屏障輸送藥物。它經營着一個獲得許可的內部研究實驗室，並擁有知識產權組合，在全球範圍內已獲得23項專利，約50項專利正在申請中。Lexaria Bioscience Corp.成立於2004年，總部設在加拿大基洛納。
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
接受Genmab A/S日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Genmab A/S和相關公司的最新新聞和分析師評級的每日簡要摘要。